Values as of: 2025-02-22
FUND | Asset Management |
Last Closing
USD 20.76Change
0.00 (0.00)%Market Cap
USD 0.64BVolume
0.11MAnalyst Target
N/AVerdict
Verdict
Tekla Healthcare Opportunities Fund is a closed ended balanced mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity and fixed income markets across the globe. It seeks to invest in securities of companies operating in the healthcare sector. The fund also invests in pooled investment vehicles. For its fixed income portion, the fund invests in corporate debt securities across the credit rating spectrum. It benchmarks the performance of its portfolio against the S&P 1500 Healthcare Index and S&P 500 Index. Tekla Healthcare Opportunities Fund was formed on April 2, 2014 and is domiciled in the United States.
Company Website : http://www.teklacap.com/thq.html
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| BX | Blackstone Group Inc |
N/A |
USD 207.93B |
| BLK | BlackRock Inc |
N/A |
USD 166.57B |
| KKR | KKR & Co LP |
N/A |
USD 137.14B |
| APO | Apollo Global Management LLC C.. |
N/A |
USD 96.74B |
| BN | Brookfield Corp |
N/A |
USD 92.48B |
| ARES | Ares Management LP |
N/A |
USD 58.28B |
| AMP | Ameriprise Financial Inc |
N/A |
USD 52.27B |
| OWL | Blue Owl Capital Inc |
N/A |
USD 36.99B |
| RJF | Raymond James Financial Inc. |
N/A |
USD 32.75B |
| BAM | Brookfield Asset Management In.. |
N/A |
USD 25.19B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| YYY | Amplify High Income ETF | 3.34 % | 0.50 % |
N/A |
USD 0.56B |
| FCEF | First Trust Income Opport.. | 0.00 % | 0.85 % |
N/A |
USD 0.04B |
| Market Performance vs. Industry/Classification (Asset Management) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 10.02% | 94% | A | 89% | A- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 10.02% | 94% | A | 89% | A- | ||
| Trailing 12 Months | |||||||
| Capital Gain | 4.22% | 49% | F | 49% | F | ||
| Dividend Return | 7.23% | 61% | D- | 85% | B | ||
| Total Return | 11.45% | 50% | F | 58% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 11.31% | 87% | B+ | 53% | F | ||
| Dividend Return | 37.16% | 71% | C- | 89% | A- | ||
| Total Return | 48.48% | 85% | B | 63% | D | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 4.38% | 76% | C+ | 48% | F | ||
| Dividend Return | 10.87% | 78% | C+ | 61% | D- | ||
| Total Return | 6.49% | 70% | C- | 89% | A- | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 19.71% | 64% | D | 55% | F | ||
| Risk Adjusted Return | 55.16% | 80% | B- | 68% | D+ | ||
| Market Capitalization | 0.64B | 63% | D | 51% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
There is nothing we particularly dislike
